Clinical Trials Finder

My Profile

Update your profile and manage your search and notification preferences

Country*
Choose country*
Sex*
Age*
Your treatment status
Select...
Mobility
Select...

My search preferences

Preferred Study Status
All
Preferred Study Type
All

My notifications

Back to Map
RECRUITING
Updated: Jan 12, 2026

Long Read Analysis in Spinal Muscular Atrophy - LOREASI (LOREASI)

Phase
N/A
Early 1
1
2
3
4

Brief Summary

Spinal Muscular Atrophy (SMA) is a severe neuromuscular disease caused by deletion of the SMN1 gene, with the most severe form leading to death in children without treatment. Genetic counselling to detect couples where both partners are carriers is particularly important. In some countries, preconception screening is offered. However, some carriers escape detection due to the existence of two copies of the SMN1 gene side-by-side (2+0 genotype). Currently, no molecular genetic methods used for diagnostic purposes can detect these 2+0 genotypes, which pose a significant challenge in genetic counselling.

This study aims to use new technologies based on the analysis of ultra-long molecules to detect side-by-side duplications of the SMN1 gene to detect heterozygous subjects not identified by current techniques and improve genetic counselling.

Key Information

Inclusion Criteria:

• Adult Subject:

  • Subject with either:

    • 1 or 3 copies of the SMN1 gene (control group) and a variable number of copies of the SMN2 gene
    • 2 copies of the SMN1 gene in cis (2+0 genotype) (test group)
  • Affiliation to French health insurance

  • Signed consent form

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Individuals deprived of liberty by an administrative or judicial decision, or those under guardianship or curatorship

Newsletter sign up

Keep up-to-date with our news, actions and events. Sign up to receive our digital newsletter.

Contact SMA Europe

Subscribe to SMA Europe Newsletter